Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Axcella Health names Alison Schecter as President of R&D » 16:22
03/03/21
03/03
16:22
03/03/21
16:22
AXLA

Axcella Health

$5.68 /

+0.1 (+1.79%)

Axcella announced the…

Axcella announced the appointment of Alison D. Schecter, M.D., as the company's President of Research and Development. In this role, Dr. Schecter will oversee all of the company's research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company's Chief Medical Officer to pursue another opportunity.

ShowHide Related Items >><<
AXLA Axcella Health
$5.68 /

+0.1 (+1.79%)

AXLA Axcella Health
$5.68 /

+0.1 (+1.79%)

11/18/20 Roth Capital
Axcella Health initiated with a Buy at Roth Capital
10/27/20
Fly Intel: Top five analyst initiations
10/27/20 Chardan
Axcella Health initiated with a Buy at Chardan
10/26/20 SVB Leerink
Axcella Health assumed with an Outperform at SVB Leerink
AXLA Axcella Health
$5.68 /

+0.1 (+1.79%)

  • 14
    May
AXLA Axcella Health
$5.68 /

+0.1 (+1.79%)

Initiation
Fly Intel: Top five analyst initiations » 09:53
03/03/21
03/03
09:53
03/03/21
09:53
COIN

Coinbase

$0.00 /

+ (+0.00%)

, CURI

CuriosityStream

$19.04 /

+0.37 (+1.98%)

, EQ

Equillium

$7.40 /

+0.2 (+2.78%)

, ONEW

OneWater Marine

$37.40 /

+0.065 (+0.17%)

, BCO

Brink's

$77.96 /

+0.21 (+0.27%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Coinbase (COIN) initiated with a Buy at DA Davidson. 2. CuriosityStream (CURI) initiated with a Buy at Needham. 3. Equillium (EQ) initiated with a Buy at JonesTrading. 4. OneWater Marine (ONEW) initiated with an Overweight at KeyBanc. 5. Brink's (BCO) reinstated with a Buy at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
ONEW OneWater Marine
$37.40 /

+0.065 (+0.17%)

EQ Equillium
$7.40 /

+0.2 (+2.78%)

CURI CuriosityStream
$19.04 /

+0.37 (+1.98%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BCO Brink's
$77.96 /

+0.21 (+0.27%)

COIN Coinbase
$0.00 /

+ (+0.00%)

03/03/21 DA Davidson
Coinbase initiated with a Buy at DA Davidson
CURI CuriosityStream
$19.04 /

+0.37 (+1.98%)

03/03/21 Needham
CuriosityStream initiated with a Buy at Needham
03/03/21 Needham
CuriosityStream initiated with a Buy at Needham
02/16/21
Fly Intel: Top five analyst initiations
02/16/21 Roth Capital
CuriosityStream initiated with a Buy at Roth Capital
EQ Equillium
$7.40 /

+0.2 (+2.78%)

03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
ONEW OneWater Marine
$37.40 /

+0.065 (+0.17%)

03/03/21 KeyBanc
OneWater Marine initiated with an Overweight at KeyBanc
02/22/21 Stifel
OneWater Marine initiated with a Buy at Stifel
02/08/21 Baird
OneWater Marine price target raised to $40 from $36 at Baird
01/27/21 Truist
OneWater Marine price target raised to $40 from $36 at Truist
BCO Brink's
$77.96 /

+0.21 (+0.27%)

03/03/21 Goldman Sachs
Brink's reinstated with a Buy at Goldman Sachs
01/15/21 Truist
Brink's price target raised to $96 from $90 at Truist
12/15/20 Truist
Brink's price target raised to $90 from $80 at Truist
05/18/20 Standpoint Research
Brink's upgraded to Buy from Hold at Standpoint Research
ONEW OneWater Marine
$37.40 /

+0.065 (+0.17%)

EQ Equillium
$7.40 /

+0.2 (+2.78%)

BCO Brink's
$77.96 /

+0.21 (+0.27%)

  • 04
    Feb
  • 18
    Sep
  • 14
    Aug
COIN Coinbase
$0.00 /

+ (+0.00%)

ONEW OneWater Marine
$37.40 /

+0.065 (+0.17%)

EQ Equillium
$7.40 /

+0.2 (+2.78%)

CURI CuriosityStream
$19.04 /

+0.37 (+1.98%)

COIN Coinbase
$0.00 /

+ (+0.00%)

CURI CuriosityStream
$19.04 /

+0.37 (+1.98%)

Recommendations
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink » 08:48
03/03/21
03/03
08:48
03/03/21
08:48
PTGX

Protagonist Therapeutics

$29.40 /

+2.63 (+9.82%)

, MORF

Morphic

$70.99 /

-13.82 (-16.30%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz raised the firm's price target on Protagonist Therapeutics (PTGX) to $41 from $30 and keeps an Outperform rating on the shares. Up about 25% over the past two days likely on positive read-through from Morphic's (MORF) oral anti-integrin Phase 1 results, the analyst believes there is still more value to be created for Protagonist's "underappreciated" Inflammatory Bowel Disease/IBD assets including PN-943, a potentially first-in-class oral anti-integrin for IBD.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$29.40 /

+2.63 (+9.82%)

MORF Morphic
$70.99 /

-13.82 (-16.30%)

PTGX Protagonist Therapeutics
$29.40 /

+2.63 (+9.82%)

01/06/21 JPMorgan
Protagonist Therapeutics initiated with an Overweight at JPMorgan
12/18/20 Piper Sandler
Hematologists excited about Protagonist's PTG-300, says Piper Sandler
12/16/20 Piper Sandler
Protagonist Therapeutics initiated with an Overweight at Piper Sandler
12/07/20 BMO Capital
Protagonist Therapeutics price target raised to $46 from $37 at BMO Capital
MORF Morphic
$70.99 /

-13.82 (-16.30%)

03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
PTGX Protagonist Therapeutics
$29.40 /

+2.63 (+9.82%)

MORF Morphic
$70.99 /

-13.82 (-16.30%)

  • 03
    Mar
  • 11
    Dec
  • 12
    May
MORF Morphic
$70.99 /

-13.82 (-16.30%)

Initiation
Equillium initiated with a Buy at JonesTrading » 07:20
03/03/21
03/03
07:20
03/03/21
07:20
EQ

Equillium

$7.20 /

-0.25 (-3.36%)

JonesTrading analyst…

JonesTrading analyst Prakhar Agrawal initiated coverage of Equillium with a Buy rating and $14 price target. Lead asset Itolizumab, which is in Phase 1 trials in acute graft-versus-host disease, or GVHD, as well as for lupus/lupus nephritis and asthma, has shown high response rates in a very sick acute GVHD population, which "bodes well for success," said Agrawal. The analyst assigns 65% odds of success to Itolizumabin in aGVHD and forecasts unadjusted peak sales in that indication of $415M.

ShowHide Related Items >><<
EQ Equillium
$7.20 /

-0.25 (-3.36%)

EQ Equillium
$7.20 /

-0.25 (-3.36%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
EQ Equillium
$7.20 /

-0.25 (-3.36%)

  • 14
    Aug
EQ Equillium
$7.20 /

-0.25 (-3.36%)

Hot Stocks
Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint » 06:51
03/03/21
03/03
06:51
03/03/21
06:51
LLY

Eli Lilly

$204.13 /

-2.26 (-1.10%)

, INCY

Incyte

$78.57 /

-1.12 (-1.41%)

Eli Lilly (LLY) and…

Eli Lilly (LLY) and Incyte (INCY) announced top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata, or AA. Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received breakthrough therapy designation from the FDA for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint. There are currently no FDA-approved treatments for AA. This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool, or SALT, score of 50 and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S. Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis, or RA, and atopic dermatitis, or AD. No deaths, major adverse cardiovascular events, or MACE, or venous thromboembolic events, or VTEs, were reported in the study. BRAVE-AA2 is the first Phase 3 study with "positive" results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD. Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as Olumiant in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus, juvenile idiopathic arthritis and COVID-19.

ShowHide Related Items >><<
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
INCY Incyte
$78.57 /

-1.12 (-1.41%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

Periodicals
Some Catholic bishops advise against certain Covid-19 vaccines, WSJ reports » 06:14
03/03/21
03/03
06:14
03/03/21
06:14
JNJ

Johnson & Johnson

$159.01 /

-0.32 (-0.20%)

, MRNA

Moderna

$146.61 /

-10.81 (-6.87%)

, PFE

Pfizer

$33.51 /

-0.185 (-0.55%)

At least two Catholic…

At least two Catholic bishops in the U.S. are advising their parishioners to avoid certain Covid-19 vaccines, The Wall Street Journal's Ian Lovett reports. The Archdiocese of New Orleans last week released a statement advising Catholics that the Johnson & Johnson (JNJ) vaccine is "morally compromised as it uses the abortion-derived cell line in development and production of the vaccine as well as the testing," and advises them to opt for a vaccine made by Moderna (MRNA) or Pfizer (PFE), if possible. A spokesman for J&J said it manufactures vaccine doses using "our engineered cell-line system" and didn't comment on the archdiocese's statement. In December, the Vatican issued a statement deeming it "morally acceptable to receive Covid-19 vaccines that have used cell lines from aborted fetuses in their research and production process" when no "ethically irreproachable" vaccines were available. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$33.51 /

-0.185 (-0.55%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRNA Moderna
$146.61 /

-10.81 (-6.87%)

03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
02/25/21 Piper Sandler
Moderna transitioning into profitable company, says Piper Sandler
PFE Pfizer
$33.51 /

-0.185 (-0.55%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
PFE Pfizer
$33.51 /

-0.185 (-0.55%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

  • 19
    May
PFE Pfizer
$33.51 /

-0.185 (-0.55%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

Conference/Events
Raymond James to hold a virtual conference » 04:55
03/03/21
03/03
04:55
03/03/21
04:55
JLL

Jones Lang LaSalle

$178.34 /

-0.7 (-0.39%)

, PODD

Insulet

$266.20 /

-4.54 (-1.68%)

, SMG

Scotts Miracle-Gro

$216.58 /

-8.37 (-3.72%)

, IDXX

Idexx Laboratories

$529.63 /

-7.96 (-1.48%)

, APLS

Apellis

$45.60 /

-2.13 (-4.46%)

, AVT

Avnet

$38.79 /

-0.62 (-1.57%)

, SBAC

SBA Communications

$246.29 /

-1.45 (-0.59%)

, LPTX

Leap Therapeutics

$2.36 /

-0.06 (-2.48%)

, RJF

Raymond James

$118.27 /

-2.71 (-2.24%)

, WY

Weyerhaeuser

$33.80 /

-1.26 (-3.59%)

, LZB

La-Z-Boy

$41.30 /

-0.7 (-1.67%)

, DXCM

DexCom

$391.96 /

-4.42 (-1.12%)

, ADMA

ADMA Biologics

$2.36 /

-0.045 (-1.87%)

, CTT

CatchMark Timber

$10.51 /

-0.08 (-0.76%)

, CACI

CACI

$219.02 /

-8.08 (-3.56%)

, BR

Broadridge

$143.68 /

-2.765 (-1.89%)

, CWST

Casella Waste

$61.15 /

+0.6 (+0.99%)

, FLXN

Flexion

$11.09 /

-0.32 (-2.80%)

, HOLX

Hologic

$74.81 /

+0.2 (+0.27%)

, VSAT

ViaSat

$52.77 /

-0.08 (-0.15%)

42nd Annual Institutional…

42nd Annual Institutional Investors Virtual Conference will be held on March 1-3.

ShowHide Related Items >><<
WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

RJF Raymond James
$118.27 /

-2.71 (-2.24%)

PODD Insulet
$266.20 /

-4.54 (-1.68%)

LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

LPTX Leap Therapeutics
$2.36 /

-0.06 (-2.48%)

JLL Jones Lang LaSalle
$178.34 /

-0.7 (-0.39%)

IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

FLXN Flexion
$11.09 /

-0.32 (-2.80%)

DXCM DexCom
$391.96 /

-4.42 (-1.12%)

CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

CACI CACI
$219.02 /

-8.08 (-3.56%)

BR Broadridge
$143.68 /

-2.765 (-1.89%)

AVT Avnet
$38.79 /

-0.62 (-1.57%)

APLS Apellis
$45.60 /

-2.13 (-4.46%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

JLL Jones Lang LaSalle
$178.34 /

-0.7 (-0.39%)

02/26/21 JPMorgan
Jones Lang LaSalle price target raised to $200 from $176 at JPMorgan
01/25/21 Goldman Sachs
Jones Lang LaSalle initiated with a Buy at Goldman Sachs
12/21/20 JPMorgan
Jones Lang LaSalle price target raised to $172 from $132 at JPMorgan
10/07/20 Keefe Bruyette
Jones Lang LaSalle downgraded to Market Perform at Keefe Bruyette
PODD Insulet
$266.20 /

-4.54 (-1.68%)

02/25/21 Oppenheimer
Insulet price target raised to $277 from $235 at Oppenheimer
02/24/21 Raymond James
Insulet price target raised to $296 from $282 at Raymond James
02/04/21 Piper Sandler
Tandem trades at 'significant discount' to Insulet, says Piper Sandler
01/29/21 Piper Sandler
Insulet downgraded to Neutral from Overweight at Piper Sandler
SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

02/04/21 Truist
Scotts Miracle-Gro price target raised to $270 from $250 at Truist
01/11/21 Raymond James
Scotts Miracle-Gro price target raised to $274 from $224 at Raymond James
01/07/21 Truist
Scotts Miracle-Gro price target raised to $250 from $180 at Truist
12/11/20
Fly Intel: Top five analyst upgrades
IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

02/17/21 Barclays
Idexx Laboratories initiated with an Overweight at Barclays
01/29/21 JPMorgan
Idexx Laboratories initiated with an Overweight at JPMorgan
08/17/20 Credit Suisse
Idexx Laboratories price target raised to $422 from $415 at Credit Suisse
08/04/20 Credit Suisse
Idexx Laboratories price target raised to $415 from $300 at Credit Suisse
APLS Apellis
$45.60 /

-2.13 (-4.46%)

01/29/21 Baird
Apellis assumed at Outperform at Baird
12/14/20 Roth Capital
Apellis price target raised to $73 from $50 at Roth Capital
12/10/20 Cowen
Apellis price target raised to $55 from $45 at Cowen
12/04/20 JPMorgan
Apellis price target raised to $87 from $50 at JPMorgan
AVT Avnet
$38.79 /

-0.62 (-1.57%)

02/23/21 Citi
Citi opens long Arrow Electronics, short Avnet pair trade
01/29/21 Loop Capital
Avnet price target raised to $39 from $32 at Loop Capital
01/19/21 Citi
Citi boosts Avnet target to $40, opens 'Positive Catalyst Watch'
12/14/20 Goldman Sachs
Avnet price target raised to $25 from $23 at Goldman Sachs
SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

02/23/21 Credit Suisse
SBA Communications price target lowered to $277 from $291 at Credit Suisse
02/23/21 Barclays
SBA Communications price target raised to $310 from $305 at Barclays
02/23/21 Deutsche Bank
SBA Communications price target lowered to $325 from $335 at Deutsche Bank
02/08/21 JPMorgan
JPMorgan downgrades SBA to Neutral on 'lukewarm' tower stance
LPTX Leap Therapeutics
$2.36 /

-0.06 (-2.48%)

01/29/21 Baird
Leap Therapeutics assumed at Outperform at Baird
06/29/20 Piper Sandler
Leap Therapeutics initiated with an Overweight at Piper Sandler
RJF Raymond James
$118.27 /

-2.71 (-2.24%)

01/29/21 Citi
Citi opens 'Positive Catalyst Watch' on Raymond James, ups price target
01/15/21 Wells Fargo
Raymond James double upgraded to Overweight at Wells Fargo
01/15/21 Wells Fargo
Raymond James upgraded to Overweight from Underweight at Wells Fargo
01/05/21 Wolfe Research
Raymond James upgraded to Outperform from Peer Perform at Wolfe Research
WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

02/01/21 DA Davidson
Weyerhaeuser price target raised to $34 from $29 at DA Davidson
12/04/20 Raymond James
Weyerhaeuser upgraded to Outperform from Market Perform at Raymond James
08/03/20
Fly Intel: Top five analyst downgrades
08/03/20 DA Davidson
Weyerhaeuser downgraded to Neutral from Buy at DA Davidson
LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

11/19/20 Raymond James
La-Z-Boy price target raised to $46 from $37 at Raymond James
10/19/20 Sidoti
La-Z-Boy upgraded to Buy from Neutral at Sidoti
06/25/20 Stifel
La-Z-Boy price target raised to $37 from $25 at Stifel
04/13/20 Sidoti
La-Z-Boy downgraded to Neutral from Buy at Sidoti
DXCM DexCom
$391.96 /

-4.42 (-1.12%)

02/12/21 Oppenheimer
DexCom price target raised to $449 from $415 at Oppenheimer
02/12/21 Citi
DexCom price target lowered to $480 from $485 at Citi
02/12/21 Piper Sandler
DexCom earnings selloff should be bought, says Piper Sandler
01/29/21 Piper Sandler
DexCom price target raised to $500 from $465 at Piper Sandler
ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
CTT CatchMark Timber
$10.51 /

-0.08 (-0.76%)

02/16/21 B. Riley Securities
CatchMark Timber price target raised to $12.50 from $11 at B. Riley
02/12/21 RBC Capital
CatchMark Timber cut to Sector Perform at RBC Capital on more limited growth
02/12/21 RBC Capital
CatchMark Timber downgraded to Sector Perform from Outperform at RBC Capital
10/30/20 RBC Capital
CatchMark Timber upgraded to Outperform from Sector Perform at RBC Capital
CACI CACI
$219.02 /

-8.08 (-3.56%)

02/23/21 William Blair
William Blair reiterates Outperform on Leidos following quarterly results
01/29/21 Truist
CACI price target raised to $290 from $275 at Truist
01/27/21 Stifel
CACI 'very likely' to bid on Perspecta as well, says Stifel
09/22/20 JPMorgan
JPMorgan upgrades 'relatively resilient' CACI to Overweight
BR Broadridge
$143.68 /

-2.765 (-1.89%)

02/03/21 BTIG
Broadridge upgraded to Buy from Neutral at BTIG
12/18/20 Truist
Broadridge initiated with a Buy at Truist
12/18/20 Truist
Broadridge initiated with a Buy at Truist
08/17/20 JPMorgan
Broadridge price target raised to $152 from $142 at JPMorgan
CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

12/21/20
Fly Intel: Top five analyst initiations
12/21/20 BofA
Casella Waste initiated with a Neutral at BofA
10/15/20 Berenberg
Casella Waste initiated with a Buy at Berenberg
09/24/20 Stifel
Casella Waste upgraded to Buy at Stifel, in a position to sustain 7%-8% growth
FLXN Flexion
$11.09 /

-0.32 (-2.80%)

08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Credit Suisse
Flexion initiated with an Outperform at Credit Suisse
HOLX Hologic
$74.81 /

+0.2 (+0.27%)

02/22/21 BTIG
Hologic price target raised to $91 from $84 at BTIG
01/28/21 Wells Fargo
Hologic price target raised to $95 from $90 at Wells Fargo
12/08/20 Argus
Hologic price target raised to $100 from $85 at Argus
11/20/20
Fly Intel: Top five analyst downgrades
VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

02/12/21 Barclays
ViaSat price target raised to $65 from $53 at Barclays
02/05/21 William Blair
William Blair upgrades ViaSat, sees upside to $90-$110 per share
02/05/21 William Blair
ViaSat upgraded to Outperform from Market Perform at William Blair
01/07/21 William Blair
ViaSat win at Delta likely brings large upfront cost, says William Blair
WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

RJF Raymond James
$118.27 /

-2.71 (-2.24%)

PODD Insulet
$266.20 /

-4.54 (-1.68%)

LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

LPTX Leap Therapeutics
$2.36 /

-0.06 (-2.48%)

JLL Jones Lang LaSalle
$178.34 /

-0.7 (-0.39%)

IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

FLXN Flexion
$11.09 /

-0.32 (-2.80%)

DXCM DexCom
$391.96 /

-4.42 (-1.12%)

CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

CTT CatchMark Timber
$10.51 /

-0.08 (-0.76%)

CACI CACI
$219.02 /

-8.08 (-3.56%)

BR Broadridge
$143.68 /

-2.765 (-1.89%)

AVT Avnet
$38.79 /

-0.62 (-1.57%)

APLS Apellis
$45.60 /

-2.13 (-4.46%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

  • 21
    Oct
  • 18
    Jun
  • 21
    May
  • 13
    May
SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

RJF Raymond James
$118.27 /

-2.71 (-2.24%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

DXCM DexCom
$391.96 /

-4.42 (-1.12%)

CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

APLS Apellis
$45.60 /

-2.13 (-4.46%)

WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

Recommendations
Piper 'increasingly bullish' on Axonics after closer look at deal » 04:46
03/03/21
03/03
04:46
03/03/21
04:46
AXNX

Axonics

$54.56 /

+1.19 (+2.23%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder is "increasingly bullish" on Axonics after taking a closer look at its acquisition of Contura. Maeder says that while the deal came as a bit of a surprise, he sees a "strong strategic fit and potentially disruptive technology in a large, underpenetrated market." The analyst's initial physician diligence came back "very positive," leaving Maeder believing that Contura's Bulkamid has the potential to be a "disruptive product" in the stress urinary incontinence market. The analyst keeps an Overweight rating on Axonics with a $64 price target.

ShowHide Related Items >><<
AXNX Axonics
$54.56 /

+1.19 (+2.23%)

AXNX Axonics
$54.56 /

+1.19 (+2.23%)

01/26/21 Baird
Axonics price target raised to $65 from $58 at Baird
01/26/21 Piper Sandler
Axonics price target raised to $64 from $57 at Piper Sandler
01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
12/01/20 BofA
ShockWave Medical downgraded to Neutral from Buy at BofA
AXNX Axonics
$54.56 /

+1.19 (+2.23%)

  • 08
    May
AXNX Axonics
$54.56 /

+1.19 (+2.23%)

Tuesday
Recommendations
Helios Technologies price target raised to $82 from $72 at Baird » 17:05
03/02/21
03/02
17:05
03/02/21
17:05
HLIO

Helios Technologies

$68.89 /

+1.295 (+1.92%)

Baird analyst Mircea…

Baird analyst Mircea Dobre raised the firm's price target on Helios Technologies to $82 from $72 and keeps an Outperform rating on the shares. The analyst notes that the company's early days of Balboa Water Group ownership are proving fruitful, providing meaningful upside to estimates and contributing to operating beat. Dobre adds that the guidance for 2021 introduced by Helios management is above consensus, and he sees further upside to high-single-digit core growth estimate given "broad end-market improvements" and pricing potential.

ShowHide Related Items >><<
HLIO Helios Technologies
$68.89 /

+1.295 (+1.92%)

HLIO Helios Technologies
$68.89 /

+1.295 (+1.92%)

10/12/20 Baird
Helios Technologies upgraded to Outperform from Neutral at Baird
05/29/20 Morgan Stanley
Morgan Stanley upgrades Helios to Equal Weight following underperformance
05/29/20 Morgan Stanley
Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
03/27/20 Truist
Helios Technologies price target lowered to $36 from $45 at SunTrust
HLIO Helios Technologies
$68.89 /

+1.295 (+1.92%)

HLIO Helios Technologies
$68.89 /

+1.295 (+1.92%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 13:01
03/02/21
03/02
13:01
03/02/21
13:01
LLY

Eli Lilly

$207.50 /

+1.11 (+0.54%)

Analysts discuss Eli…

Analysts discuss Eli Lilly's Alzheimer's Disease Drug, Donanemab and the real-world clnical implications with Paul R. Solomon, PhD on an Analyst/Industry conference call to be held on March 5.

ShowHide Related Items >><<
LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.